A one-year weight management programme for difficult-to-treat asthma with obesity: a randomised controlled study.

IF 9.5 1区医学 Q1 CRITICAL CARE MEDICINE

Chest Pub Date : 2024-10-18 DOI:10.1016/j.chest.2024.09.042

Varun Sharma, Helen Clare Ricketts, Louise McCombie, Naomi Brosnahan, Luisa Crawford, Lesley Slaughter, Anna Goodfellow, Femke Steffensen, Rekha Chaudhuri, Michael E J Lean, Douglas C Cowan

{"title":"A one-year weight management programme for difficult-to-treat asthma with obesity: a randomised controlled study.","authors":"Varun Sharma, Helen Clare Ricketts, Louise McCombie, Naomi Brosnahan, Luisa Crawford, Lesley Slaughter, Anna Goodfellow, Femke Steffensen, Rekha Chaudhuri, Michael E J Lean, Douglas C Cowan","doi":"10.1016/j.chest.2024.09.042","DOIUrl":null,"url":null,"abstract":"Background: Obesity-associated asthma results in increased morbidity and mortality. We report one-year asthma outcomes with the Counterweight-Plus weight management programme (CWP) compared to usual care (UC) in a single-centre, randomised, controlled trial in patients with difficult-to-treat asthma and obesity.Research question: Can CWP use result in improved asthma control and quality of life compared to UC at one-year in patients with difficult-to-treat asthma and obesity?Study design and methods: We randomised (1:1 CWP:UC) adults with difficult-to-treat asthma and body mass index ≥30kg/m2. CWP with dietitian support: 12-week total diet replacement phase (850kcal/day low-energy formula); food reintroduction and maintenance phases up to one-year. Outcomes include Asthma Control Questionnaire (ACQ-6), Asthma Quality of Life Questionnaire (AQLQ) and healthcare usage. Minimal clinically important difference (MCID) is 0.5 for ACQ-6 and AQLQ.Results: Of 36 recruited, 29 attended at 52-weeks: 13 CWP, 16 UC. CWP resulted in greater weight change (median -14kg [IQR -15, -9]) compared to UC (2kg [-7, 8]; p=0.015) at 52-weeks. A greater proportion achieved MCID with CWP vs UC in AQLQ (71% vs 6% respectively; p<0.001). No between-group differences were observed in ACQ-6. Median exacerbation frequency reduced over 52-weeks with CWP from 4 (IQR 2, 5) to 0 (0, 2) (p<0.001), though no between-group difference was observed. 70% of the CWP group lost ≥10% body weight and had improvement in ACQ-6 (mean difference -1.1, 95%CI -1.9, -0.3; p=0.018) and AQLQ (1.2, 95%CI 0.4, 2.1; p=0.011) across 52-weeks.Interpretation: Use of a dietitian-supported weight management programme results in sustained weight-loss and is a potential treatment for obesity in asthma. CWP resulted in a higher proportion achieving MCID improvement in AQLQ compared to UC. Within group differences in AQLQ and exacerbation frequency suggest potential with CWP. These encouraging signals justify a larger sample study to further assess asthma-related outcomes.","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":""},"PeriodicalIF":9.5000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chest","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.chest.2024.09.042","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Obesity-associated asthma results in increased morbidity and mortality. We report one-year asthma outcomes with the Counterweight-Plus weight management programme (CWP) compared to usual care (UC) in a single-centre, randomised, controlled trial in patients with difficult-to-treat asthma and obesity.

Research question: Can CWP use result in improved asthma control and quality of life compared to UC at one-year in patients with difficult-to-treat asthma and obesity?

Study design and methods: We randomised (1:1 CWP:UC) adults with difficult-to-treat asthma and body mass index ≥30kg/m². CWP with dietitian support: 12-week total diet replacement phase (850kcal/day low-energy formula); food reintroduction and maintenance phases up to one-year. Outcomes include Asthma Control Questionnaire (ACQ-6), Asthma Quality of Life Questionnaire (AQLQ) and healthcare usage. Minimal clinically important difference (MCID) is 0.5 for ACQ-6 and AQLQ.

Results: Of 36 recruited, 29 attended at 52-weeks: 13 CWP, 16 UC. CWP resulted in greater weight change (median -14kg [IQR -15, -9]) compared to UC (2kg [-7, 8]; p=0.015) at 52-weeks. A greater proportion achieved MCID with CWP vs UC in AQLQ (71% vs 6% respectively; p<0.001). No between-group differences were observed in ACQ-6. Median exacerbation frequency reduced over 52-weeks with CWP from 4 (IQR 2, 5) to 0 (0, 2) (p<0.001), though no between-group difference was observed. 70% of the CWP group lost ≥10% body weight and had improvement in ACQ-6 (mean difference -1.1, 95%CI -1.9, -0.3; p=0.018) and AQLQ (1.2, 95%CI 0.4, 2.1; p=0.011) across 52-weeks.

Interpretation: Use of a dietitian-supported weight management programme results in sustained weight-loss and is a potential treatment for obesity in asthma. CWP resulted in a higher proportion achieving MCID improvement in AQLQ compared to UC. Within group differences in AQLQ and exacerbation frequency suggest potential with CWP. These encouraging signals justify a larger sample study to further assess asthma-related outcomes.

查看原文本刊更多论文

针对难治性肥胖哮喘的为期一年的体重管理计划：随机对照研究。

背景：肥胖引起的哮喘会增加发病率和死亡率。我们报告了在一项单中心随机对照试验中，Counterweight-Plus 体重管理计划（CWP）与常规护理（UC）相比，对难以治疗的哮喘和肥胖患者一年的哮喘治疗结果：研究问题：对于难以治疗的哮喘和肥胖症患者，使用 CWP 一年后，其哮喘控制率和生活质量能否比常规护理有所提高？我们对哮喘难以治愈且体重指数≥30kg/m2的成人患者进行了随机分组（1:1 CWP:UC）。有营养师支持的 CWP：为期 12 周的全面饮食替代阶段（850 千卡/天的低能量配方）；食物再引入和维持阶段，最长一年。结果包括哮喘控制问卷（ACQ-6）、哮喘生活质量问卷（AQLQ）和医疗保健使用情况。ACQ-6 和 AQLQ 的最小临床重要差异（MCID）为 0.5：在招募的 36 人中，29 人参加了 52 周的治疗：13 人参加了 CWP，16 人参加了 UC。在 52 周时，CWP 与 UC（2 千克 [-7, 8]；P=0.015）相比，体重变化更大（中位数 -14 千克 [IQR -15, -9]）。CWP与UC相比，在AQLQ方面达到MCID的比例更高（分别为71%对6%；P解释：使用营养师支持的体重管理计划可持续减轻体重，是治疗哮喘患者肥胖症的一种潜在方法。与 UC 相比，CWP 可使更高比例的患者在 AQLQ 方面获得 MCID 改善。AQLQ和恶化频率的组内差异表明，CWP具有潜力。这些令人鼓舞的信号表明，有必要进行更大规模的样本研究，以进一步评估与哮喘相关的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chest 医学-呼吸系统

CiteScore

13.70

自引率

3.10%

发文量

3369

审稿时长

15 days

期刊介绍： At CHEST, our mission is to revolutionize patient care through the collaboration of multidisciplinary clinicians in the fields of pulmonary, critical care, and sleep medicine. We achieve this by publishing cutting-edge clinical research that addresses current challenges and brings forth future advancements. To enhance understanding in a rapidly evolving field, CHEST also features review articles, commentaries, and facilitates discussions on emerging controversies. We place great emphasis on scientific rigor, employing a rigorous peer review process, and ensuring all accepted content is published online within two weeks.